Top Markets
Coin of the day
Carmell Therapeutics Corporation Carmell Therapeutics Corporation

Carmell Therapeutics Corporation

CTCX
Rang in aandelen #36666
Carmell Therapeutics Corporation (CTCX) specializes in the creation of... Carmell Therapeutics Corporation (CTCX) specializes in the creation of plasma-based bioactive materials (PBMs) aimed at catalyzing tissue regeneration and repair following injury, illness, or the effects of aging. Their flagship product, CT-101, is a versatile accelerant with a dual focus. For orthopedic and dental applications, it's designed to enhance bone healing in cases such as tibia fractures, foot and ankle fusions, spinal fusions, and also serves as a dental bone graft substitute and bone void filler. Furthermore, CT-101 acts as a tissue healing accelerant, addressing conditions like androgenetic alopecia (pattern baldness) and persistent chronic wounds. Established in 2008, the company operates from its headquarters in Pittsburgh, Pennsylvania.
Aandeelprijs
$0.117
Laatst gesynchroniseerd: 2025-04-04
Marktkapitalisatie
$2.45M
Verandering (1 dag)
-13.59%
Verandering (1 jaar)
0.00%
Land
US
Handel Carmell Therapeutics Corporation (CTCX)

Categorie

P/B-ratio voor Carmell Therapeutics Corporation (CTCX)
P/B-ratio op August 2026 TTM: -0.06
Volgens de meest recente financiële rapporten en aandelenkoers van Carmell Therapeutics Corporation is de huidige P/B-ratio (TTM) -0.06. Eind 2023 had het bedrijf een P/B-ratio van 95.93.
P/B-ratiohistoriek voor Carmell Therapeutics Corporation van 2021 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
2026 (TTM) -0.06 -99.85%
2024 -37.13 -138.70%
2023 95.93 -161.62%
2022 -155.68 -19.29%
2021 -192.90 0.00%
P/B-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/B-ratio Verschil in P/B-ratio Land
6.3419 -11,404.63%
US
6.2413 -11,225.31%
NL
- -
CH
- -
KR
3.4612 -6,269.70%
BE